<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>With the aim of investigating <z:chebi fb="105" ids="17234">glucose</z:chebi>-mediated <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal (<z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness [GE]) in 15 (3 female and 12 male subjects) insulin-resistant normoglycemic relatives of patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DM2</z:e>), and 15 age-, sex-, and BMI-matched control subjects without a family history of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DM2</z:e>, we performed 2 studies: 1) a 5-h euglycemic near-normoinsulinemic pancreatic clamp with somatostatin (360 microg/h), insulin (0.25 mU x kg(-1) x min(-1)), glucagon (0.5 ng x kg(-1) x min(-1)), growth hormone (6 ng x kg(-1) x min(-1)), and tritiated <z:chebi fb="105" ids="17234">glucose</z:chebi> infusion and indirect calorimetry; and 2) on a separate day, an identical 5-h clamp but at <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> (approximately 12 mmol/l) over the last 2 h </plain></SENT>
<SENT sid="1" pm="."><plain>Fasting plasma insulin (PI) concentrations were elevated in the relatives compared with control subjects (49 +/- 6 vs. 32 +/- 5 pmol/l, P &lt; 0.04), whereas plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (PG) was not (5.6 +/- 0.1 vs. 5.5 +/-0.1 mmol/l) </plain></SENT>
<SENT sid="2" pm="."><plain>At the end (i.e., 4.5-5.0 h) of the euglycemic clamp (PG, 6.1 +/- 0.4 vs. 5.6 +/- 0.1 mmol/l; PI, 78 +/- 5 vs. 73 +/-6 pmol/l), peripheral <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake (Rd(euglycemia)) was decreased in the relatives (2.93 +/- 0.08 vs. 3.70 +/-0.23 mg x min(-1) x kg(-1) fat free mass [FFM], P &lt; 0.005), due to a decreased nonoxidative <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal (0.83 +/-0.21 vs. 1.62 +/- 0.19 mg x min(-1) x kg(-1) FFM, P &lt; 0.01), but hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> production (HGP) was increased (1.97 +/-0.19 vs. 1.50 +/- 0.13 mg x min(-1) x kg(-1) FFM, P &lt; 0.05) </plain></SENT>
<SENT sid="3" pm="."><plain>At the matched end of the hyperglycemic clamp (PG, 12.7 +/-0.2 vs. 12.6 +/- 0.2 mmol/l; PI, 87 +/- 5 vs. 78 +/- 7 pmol/l), peripheral <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal (Rd(<z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>)) (5.52 +/- 0.22 vs. 5.92 +/- 0.29 mg x min(-1) x kg(-1) FFM, NS), nonoxidative <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal (2.93 +/- 0.18 vs. 2.78 +/- 0.25 mg x min(-1) x kg(-1) FFM, NS), and HGP(<z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>) (1.20 +/- 0.09 vs. 1.37 +/-0.23 mg x min(-1) x kg(-1) FFM, NS) were <z:hpo ids='HP_0000001'>all</z:hpo> identical </plain></SENT>
<SENT sid="4" pm="."><plain>When the effectiveness of <z:chebi fb="105" ids="17234">glucose</z:chebi> itself on <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake and production [(Rd(<z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>) - Rd(euglycemia))/deltaPG and (HGP(euglycemia)- HGP(<z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>))/deltaPG] was calculated, the relatives had a 22% increase in peripheral uptake (0.022 +/- 0.002 vs. 0.018 +/- 0.002 mg x min(-1) x kg(-1) FFM per mg/dl), due to a significantly increased nonoxidative <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism and enhanced suppression of HGP (0.0076 +/- 0.0021 vs. 0.0011 +/- 0.0022 mg x min(-1) x kg(-1) FFM per mg/dl, P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>In conclusion, in insulin-resistant relatives of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DM2</z:e> patients, whole-body <z:chebi fb="105" ids="17234">glucose</z:chebi>-mediated <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal is increased by GE enhancement of the muscle nonoxidative <z:chebi fb="105" ids="17234">glucose</z:chebi> pathway and by GE enhancement of the suppression of HGP </plain></SENT>
<SENT sid="6" pm="."><plain>These mechanisms may represent a compensatory mechanism to the ongoing <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> of these relatives </plain></SENT>
</text></document>